| Literature DB >> 30090953 |
Hassan Askari1, Mohammad Foad Abazari2, Pegah Ghoraeian2, Sepehr Torabinejad2, Maryam Nouri Aleagha2, Reza Mirfallah Nassiri3, Farshid Tahmasebi3, Nairi Abedi4, Sulail Fatima Rajani5, Ali Salarian1, Maryam Belaran6, Mohammed Elshiekh7, Nima Sanadgol8.
Abstract
Chronic kidney disease (CKD) is a major public health problem worldwide and is associated with spatial learning deficits. The aim of the present study was to evaluate the protective effects of hydrogen sulfide (H2S) on CKD-mediated behavioral deficits with emphasis to the role of nitric oxide (NO) in these effects. Fifty rats were randomly allocated to five experimental groups including: sham, Five-sixth (5/6) nephrectomy (Nx), 5/6Nx + NaHS, 5/6Nx + NaHS+L-nitroarginine methyl ester (L-NAME), and 5/6Nx + NaHS+aminoguanidine (AMG). Twelve weeks after 5/6Nx, we evaluated proteinuria, creatinine clearance (CrCl), oxidative/antioxidant status, and hippocampus neuro-inflammation and NO synthase genes in all groups. Furthermore, training trials of all animals were conducted in the Morris water maze (MWM) task one day before animal euthanizing. As predicted, 5/6Nx induced several injuries, including enhancement of proteinuria and reduction of CCr, oxidant/antioxidant imbalance and up-regulation of TNF-α and IL-1β gene expressions in the hippocampus tissues. As predicted, 5/6Nx resulted in learning and memory impairments, and increased escape latency during acquisition trials in the MWM task. Interestingly, NaHS (H2S donor) improved behavioral deficits, renal dysfunction, accelerated anti-oxidant/anti-inflammatory responses and increased eNOS and decreased iNOS. Moreover, these effects of NaHS were prevented by L-NAME but not AMG co-administration. In conclusion, H2S ameliorates CKD-mediated brain dysfunctions, through interaction with NO signaling in the hippocampus.Entities:
Keywords: Chronic kidney disease; Cognitive dysfunction; Hydrogen sulfide; Inflammation; Nitric oxide; Oxidative stress
Mesh:
Substances:
Year: 2018 PMID: 30090953 DOI: 10.1007/s11011-018-0301-8
Source DB: PubMed Journal: Metab Brain Dis ISSN: 0885-7490 Impact factor: 3.584